CN1674913A - 乙酸阿奈可他用于在年龄相关性黄斑变性患者中保护视力的用途 - Google Patents

乙酸阿奈可他用于在年龄相关性黄斑变性患者中保护视力的用途 Download PDF

Info

Publication number
CN1674913A
CN1674913A CNA038188260A CN03818826A CN1674913A CN 1674913 A CN1674913 A CN 1674913A CN A038188260 A CNA038188260 A CN A038188260A CN 03818826 A CN03818826 A CN 03818826A CN 1674913 A CN1674913 A CN 1674913A
Authority
CN
China
Prior art keywords
acetate
patients
compound
treatment
logmar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038188260A
Other languages
English (en)
Chinese (zh)
Inventor
J·A·耶丹
P·奇利奥克斯
S·M·罗伯特松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Alcon Universal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Universal Ltd filed Critical Alcon Universal Ltd
Publication of CN1674913A publication Critical patent/CN1674913A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CNA038188260A 2002-08-05 2003-06-26 乙酸阿奈可他用于在年龄相关性黄斑变性患者中保护视力的用途 Pending CN1674913A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40122002P 2002-08-05 2002-08-05
US60/401,220 2002-08-05

Publications (1)

Publication Number Publication Date
CN1674913A true CN1674913A (zh) 2005-09-28

Family

ID=31495940

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038188260A Pending CN1674913A (zh) 2002-08-05 2003-06-26 乙酸阿奈可他用于在年龄相关性黄斑变性患者中保护视力的用途

Country Status (17)

Country Link
US (2) US20040127472A1 (https=)
EP (1) EP1539182A4 (https=)
JP (1) JP2005535691A (https=)
KR (1) KR20050026510A (https=)
CN (1) CN1674913A (https=)
AR (1) AR040599A1 (https=)
AU (1) AU2003281817A1 (https=)
BR (1) BR0313546A (https=)
CA (1) CA2494211A1 (https=)
DE (1) DE03742226T1 (https=)
ES (1) ES2244361T1 (https=)
MX (1) MXPA05000773A (https=)
PL (1) PL375024A1 (https=)
RU (1) RU2322239C2 (https=)
TW (1) TW200410699A (https=)
WO (1) WO2004012742A1 (https=)
ZA (1) ZA200500731B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101759741B (zh) * 2008-11-06 2013-01-09 天津金耀集团有限公司 一种化合物及其在制备治疗血管新生的药物中的应用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127472A1 (en) * 2002-08-05 2004-07-01 Jerdan Janice A. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
MXPA05008396A (es) * 2003-02-20 2006-03-30 Alcon Inc Formulaciones de glucocorticoides para tratar angiogenesis ocular patologica.
AU2004249256A1 (en) * 2003-06-20 2004-12-29 Alcon, Inc. Treatment of AMD with combination of ingredients
CA2539023A1 (en) * 2003-09-23 2005-04-14 Alcon Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US7257366B2 (en) * 2003-11-26 2007-08-14 Osmosis Llc System and method for teaching a new language
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
US20070134244A1 (en) * 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis
MX2009006146A (es) * 2006-12-18 2009-06-19 Alcon Res Ltd Dispositivos y metodos para la administracion de farmacos oftalmicos.
CN101923856B (zh) 2009-06-12 2012-06-06 华为技术有限公司 语音识别训练处理、控制方法及装置
US20150037422A1 (en) * 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
RU2489146C1 (ru) * 2012-07-11 2013-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения "сухой" формы возрастной макулярной дегенерации

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
RU2051651C1 (ru) * 1988-07-07 1996-01-10 Институт химии поверхности АН Украины Основа для глазных капель
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
ATE283013T1 (de) * 1999-10-21 2004-12-15 Alcon Inc Medikamentenzuführvorrichtung
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US20040127472A1 (en) * 2002-08-05 2004-07-01 Jerdan Janice A. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
US20070134244A1 (en) * 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101759741B (zh) * 2008-11-06 2013-01-09 天津金耀集团有限公司 一种化合物及其在制备治疗血管新生的药物中的应用

Also Published As

Publication number Publication date
AR040599A1 (es) 2005-04-13
BR0313546A (pt) 2005-07-12
ZA200500731B (en) 2006-08-30
RU2005106234A (ru) 2005-08-10
KR20050026510A (ko) 2005-03-15
US20060166956A1 (en) 2006-07-27
AU2003281817A1 (en) 2004-02-23
MXPA05000773A (es) 2005-04-19
TW200410699A (en) 2004-07-01
WO2004012742A1 (en) 2004-02-12
US20040127472A1 (en) 2004-07-01
PL375024A1 (en) 2005-11-14
DE03742226T1 (de) 2006-03-09
ES2244361T1 (es) 2005-12-16
JP2005535691A (ja) 2005-11-24
CA2494211A1 (en) 2004-02-12
EP1539182A1 (en) 2005-06-15
EP1539182A4 (en) 2010-01-20
RU2322239C2 (ru) 2008-04-20

Similar Documents

Publication Publication Date Title
O’Brien Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care
Nuyts et al. Histopathologic effects of mitomycin C after trabeculectomy in human glaucomatous eyes with persistent hypotony
Harbour et al. Pars plana vitrectomy for chronic pseudophakic cystoid macular edema
CN1674913A (zh) 乙酸阿奈可他用于在年龄相关性黄斑变性患者中保护视力的用途
Sivaprasad et al. Intravitreal steroids in the management of macular oedema
CN115461040A (zh) 含有酪氨酸激酶抑制剂的眼用植入物
Grzybowski et al. The role of steroids and NSAIDs in prevention and treatment of postsurgical cystoid macular edema
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
CN115066232B (zh) 用于治疗眼病的组合物和方法
CN103705524A (zh) 具有二氟泼尼酯的黄斑水肿治疗用滴眼剂
US20050043220A1 (en) Methods and compositions for treating macular degeneration
Ayyala et al. Bleb infections: clinically different courses of" blebitis" and endophthalmitis
Hyung et al. Midd-term effects of trabeculectomy with mitomycin C in neovascular glaucoma patients.
Sandoval et al. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation
Davids et al. XEN® implantation: an effective strategy to stop glaucoma progression despite prior minimally invasive glaucoma surgery
Albialy et al. Safety and efficacy of intracameral injection of dexamethasone and moxifloxacin at the end of cataract surgery
Tsuchiya et al. Three-year prospective randomized study of incidence of posterior capsule opacification in eyes treated with topical diclofenac and betamethasone
Otsuka et al. Choroidal and retinal blood flow changes following vitrectomy in two cases of postoperative endophthalmitis
Feghhi et al. Development of nano-formulating dexamethasone for anterior uveitis treatment: A randomized clinical trial study
Amer et al. Safety of prophylactic intracameral moxifloxacin during phacoemulsification
RU2758026C1 (ru) Способ хирургического лечения влажной формы макулодистрофии, осложненной вторичной эпиретинальной мембраной
Duszak Diagnosis and management of Thygeson’s superficial punctate keratitis
Alam et al. Comparison of a Preservative-free Non-steroidal Anti-inflammatory Drug and Preservative-free Corticosteroid after Uneventful Cataract Surgery: A Randomized Control Trial
Sultan et al. Efficacy of preoperative 0.1% topical nepafenac in the prevention of cystoid macular edema after cataract surgery in diabetic patients.
Low et al. A Case of Persistent Bilateral Irvine-Gass Syndrome Following Uneventful Cataract Surgery in a Healthy Individual

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication